Drug-eluting stents
![Primum non nocere. Quomo sapere? [Firstly, do no harm. How can we know this?] Drug-eluting stents versus surgery](data:image/gif;base64,R0lGODlhAQABAIAAAP///wAAACH5BAEAAAAALAAAAAABAAEAAAICRAEAOw==)
Primum non nocere. Quomo sapere? [Firstly, do no harm. How can we know this?] Drug-eluting stents versus surgery
... emplacing drug-eluting stents, compared with patients treated with revascularization surgery, showed greater mortality in the group in which drug-eluting stents were ...
2
Evolução tardia após intervenção coronária percutânea com stents farmacológicos em pacientes diabéticos do Registro DESIRE (Drug-Eluting Stents In the REal world).
... interventions. Drug-eluting stents can confer a better late evolution to this ...with drug-eluting stents between May 2002 and January ...
8
Comparing the Clinical Outcomes between Drug Eluting Stents and Bare Metal Stents in Patients with Insulin-Treated Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of 10 Randomized Controlled Trials.
... with Drug Eluting Stents (DES) or Bare Metal Stents (BMS) [3], compared to non-T2DM, other studies have shown DES to have been associated with better outcomes compared to BMS in patients with ...
15
Comparison of Bare metal Vs Drug eluting stents for in-stent Restenosis among Diabetics
... Diabetic patients treated with DES have lower risk of future need for TVR. The overall rates of angina did not differ significantly between DES and BMS-treated patients. Most importantly, our data suggest diabetic ...
5
Drug-eluting stents for acute coronary syndrome: a meta-analysis of randomized controlled trials.
... The clinical studies were eligible for inclusion if 1) study design involved patient randomization; 2) they compared second- generation DES (EES or ZES) versus first-generation DES (SES or PES) in patients with ACS ...
8
Efficacy and safety of biodegradable polymer biolimus-eluting stents versus durable polymer drug-eluting stents: a meta-analysis.
... polymer stent were not inferior when compared with the durable polymer stent in terms of late in-stent loss at 6 months [36]. Recently, a pooled analysis of individual patient data from the ISAR-TEST 3, ISAR-TEST 4, and ...
9
Fundamento e desenho do teste randomizado PAINT
... novel drug-eluting stent formulations, with a biodegradable-polymer carrier and releasing paclitaxel or sirolimus, which were compared against a bare metal stent (primary ...the drug-eluting ...
7
Rev. Bras. Cardiol. Invasiva vol.22 número4
... gradable-polymer drug-eluting stents (BP-DES) are still ...different stents, such that the results cannot be explained only by different polymers or drugs, but also by the variable metallic ...
5
Arq. Bras. Cardiol. vol.96 número6 en v96n6a16
... of Drug-Eluting Stents: Long-term Follow- up Study”, pages 348-352, by authors Vitor Osório Gomes, Patrícia Blaya, Ricardo Lasevitch, Denise Oliveira, Patrícia Hickmann, Luís Smidt, Carisi Polanczyk, ...
1
Arq. Bras. Cardiol. vol.87 número4
... with drug-eluting stents requires a longer duration of thienopyridine therapy in comparison to bare-metal ...of drug-eluting stent ...
6
Rev. Bras. Cardiol. Invasiva vol.17 número3 en v17n3a04
... metal stents in ...versus drug-eluting stents is not reported in a series, it is typically between 10 and 20% in Brazil, and this relatively low percentage use of drug eluting ...
1
Rev. Bras. Cardiol. Invasiva vol.22 número2
... with drug-eluting bal- loons has emerged as an adjunctive strategy in the setting of Interventional ...to drug-eluting stents, drug-eluting balloons offer advantages such ...
5
Arq. Bras. Cardiol. vol.93 número2 en v93n2a20
... The COURAGE trial is an example of clinical trial often missing in the current clinical scenario - the comparative effectiveness studies - and the results were stunning. The primary endpoint was all-cause mortality and ...
4
Rev. Bras. Cardiol. Invasiva vol.22 número2
... stent, of which 100 (35.2%) had multivessel coronary artery disease. This group was compared to 100 patients, of a group of 304 (38.9%) patients with multivessel coronary artery dis- ease treated with second generation ...
6
Arq. Bras. Cardiol. vol.98 número1 en v98n1a15
... As expected, patients with chronic renal failure had worse cardiovascular outcomes, which was modified with the use of drug-eluting stents. Finally, the study aimed to evaluate the evolution of renal ...
1
Braz. J. Cardiovasc. Surg. vol.21 número4 en a04v21n4
... I t is unnecessary to reiterate that there is a high prevalence of coronary artery disease in the population. The risk increases with the patient’s age and a reduction of certain diseases that were prevalent in the past. ...
3
Rev. Bras. Cardiol. Invasiva vol.20 número4 en v20n4a03
... Background: Drug-eluting stents (DES) have changed con- temporary interventional cardiology practice, enabling the approach of increasingly more complex clinical and angiographic ...
6
Rev. Bras. Cardiol. Invasiva vol.21 número3
... with drug-eluting stents (DES) from the Safira Registry; changes in the population profile and results of PCI in the Angiocardio Registry; evolution of patients with cardiogenic shock due to AMI with ...
2
Rev. Bras. Cardiol. Invasiva vol.20 número2 en a03v20n2
... in drug- eluting balloon technology. One is the drug, the other is the balloon catheter, and the last is the excipient that binds the drug to the balloon catheter surface and releases it to ...
2
Arq. Bras. Cardiol. vol.88 número4
... of drug-eluting stents just described may be enhanced in three ways: (i) increasing their clinical effectiveness – assuming the medium-term results of clinical trials, where a greater benefit could ...
10